^
    2years
    Clinical Trial to Evaluate the Safety and Efficacy of IM92 CAR-T Cells Therapy in Patients With Advanced Gastric or Pancreatic Adenocarcinoma (clinicaltrials.gov)
    P1, N=6, Recruiting, Beijing Immunochina Medical Science & Technology Co., Ltd.
    New P1 trial • CAR T-Cell Therapy • IO biomarker
    |
    CLDN18 (Claudin 18) • CA 19-9 (Cancer antigen 19-9)
    |
    CLDN18.2 positive
    |
    IM92